John G Ullman & Associates Inc Novartis Ag Transaction History

John G Ullman & Associates Inc

$649 Million
Q3 2024

A detailed history of John G Ullman & Associates Inc transactions in Novartis Ag stock. As of the latest transaction made, John G Ullman & Associates Inc holds 141,466 shares of NVS stock, worth $14.6 Million. This represents 2.51% of its overall portfolio holdings.

Number of Shares

141,466

Previous 177,248 20.19%

Holding current value

$14.6 Million

Previous $18.9 Million 13.77%

% of portfolio

2.51%

Previous 2.99%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$106.13 - $120.89 $3.8 Million - $4.33 Million	-35,782 Reduced 20.19%	141,466 $16.3 Million
Q2 2024 Aug 08, 2024	SELL	$92.57 - $107.37 $179,493 - $208,190	-1,939 Reduced 1.08%	177,248 $18.9 Million
Q1 2024 May 06, 2024	SELL	$95.27 - $108.47 $163,197 - $185,809	-1,713 Reduced 0.95%	179,187 $17.3 Million
Q4 2023 Jan 31, 2024	SELL	$92.27 - $101.54 $165,163 - $181,756	-1,790 Reduced 0.98%	180,900 $18.3 Million
Q3 2023 Nov 01, 2023	SELL	$94.73 - $105.13 $212,668 - $236,016	-2,245 Reduced 1.21%	182,690 $18.6 Million
Q2 2023 Aug 21, 2023	SELL	$92.52 - $104.91 $287,737 - $326,270	-3,110 Reduced 1.65%	184,935 $18.7 Million
Q1 2023 May 05, 2023	SELL	$80.03 - $92.81 $493,464 - $572,266	-6,166 Reduced 3.17%	188,045 $17.3 Million
Q4 2022 Feb 08, 2023	SELL	$75.55 - $92.52 $278,250 - $340,751	-3,683 Reduced 1.86%	194,211 $17.6 Million
Q3 2022 Oct 19, 2022	BUY	$74.61 - $87.26 $684,919 - $801,046	9,180 Added 4.86%	197,894 $15 Million
Q2 2022 Jul 27, 2022	BUY	$80.52 - $93.75 $184,793 - $215,156	2,295 Added 1.23%	188,714 $16 Million
Q1 2022 Apr 29, 2022	BUY	$80.11 - $90.62 $655,299 - $741,271	8,180 Added 4.59%	186,419 $16.4 Million
Q4 2021 Jan 26, 2022	BUY	$79.7 - $88.13 $261,814 - $289,507	3,285 Added 1.88%	178,239 $15.6 Million
Q3 2021 Nov 02, 2021	SELL	$81.78 - $95.14 $14,720 - $17,125	-180 Reduced 0.1%	174,954 $14.3 Million
Q2 2021 Jul 23, 2021	SELL	$85.24 - $94.15 $198,609 - $219,369	-2,330 Reduced 1.31%	175,134 $16 Million
Q1 2021 Apr 22, 2021	BUY	$83.5 - $98.47 $587,088 - $692,342	7,031 Added 4.13%	177,464 $15.2 Million
Q4 2020 Feb 05, 2021	BUY	$78.07 - $94.43 $1.48 Million - $1.79 Million	18,948 Added 12.51%	170,433 $16.1 Million
Q3 2020 Nov 06, 2020	SELL	$82.14 - $91.0 $82,140 - $91,000	-1,000 Reduced 0.66%	151,485 $13.2 Million
Q2 2020 Jul 29, 2020	SELL	$80.93 - $91.1 $28,325 - $31,884	-350 Reduced 0.23%	152,485 $13.3 Million
Q1 2020 Apr 14, 2020	SELL	$70.67 - $99.01 $177,735 - $249,010	-2,515 Reduced 1.62%	152,835 $12.6 Million
Q4 2019 Jan 29, 2020	SELL	$84.35 - $95.37 $234,071 - $264,651	-2,775 Reduced 1.75%	155,350 $14.7 Million
Q3 2019 Oct 21, 2019	SELL	$85.54 - $94.26 $57,739 - $63,625	-675 Reduced 0.43%	158,125 $13.7 Million
Q2 2019 Aug 02, 2019	SELL	$75.4 - $92.8 $43,355 - $53,360	-575 Reduced 0.36%	158,800 $14.5 Million
Q1 2019 Apr 30, 2019	SELL	$75.32 - $86.15 $184,533 - $211,067	-2,450 Reduced 1.51%	159,375 $15.3 Million
Q4 2018 Jan 29, 2019	SELL	$73.66 - $82.02 $50,309 - $56,019	-683 Reduced 0.42%	161,825 $13.9 Million
Q3 2018 Nov 02, 2018	SELL	$66.94 - $77.43 $14,057 - $16,260	-210 Reduced 0.13%	162,508 $14 Million
Q2 2018 Jul 23, 2018	BUY	$64.91 - $73.36 $173,634 - $196,238	2,675 Added 1.67%	162,718 $12.3 Million
Q1 2018 Apr 19, 2018	BUY	$70.39 - $84.15 $117,903 - $140,951	1,675 Added 1.06%	160,043 $12.9 Million
Q4 2017 Jan 31, 2018	BUY	$72.33 - $77.64 $18,661 - $20,031	258 Added 0.16%	158,368 $13.3 Million
Q3 2017 Nov 03, 2017	BUY	$74.14 - $77.27 $11.7 Million - $12.2 Million	158,110	158,110 $13.6 Million

Others Institutions Holding NVS

# of Institutions

1,425

Shares Held

131M

Call Options Held

1.12M

Put Options Held

1.83M

View Full List

About NOVARTIS AG

Ticker NVS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,151,000,064
Market Cap $222B
Description
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatol...

More about NVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of John G Ullman & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on John G Ullman & Associates Inc with notifications on news.

Account

John G Ullman & Associates Inc Novartis Ag Transaction History